Results 21 to 30 of about 180 (132)

Linking FHIR‐Based Medication Data to a Computable Algorithm for Heart Medication Optimization: A Critical Component of Any Medication Learning Health System

Learning Health Systems, Volume 10, Issue 1, January 2026.
ABSTRACT Introduction Despite strong evidence supporting guideline‐directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF), a significant gap persists in the consistent application of these therapies. This shortfall has prompted organizations like the American College of Cardiology to recommend leveraging electronic ...
Joey LeGrand, Mohamed S. Ali, Allen Flynn, Juan Arzac, Corey Lester, Michael P. Dorsch   +5 more
wiley   +1 more source

Chemerin Normal Function and Roles in Metabolic and Nonmetabolic Disorders: An Up‐To‐Date Comprehensive Review

Biochemistry Research International, Volume 2026, Issue 1, 2026.
Chemerin (retinoic acid receptor responder 2; RARRES2) is a secreted chemoattractant/adipokine that is expressed mainly in white adipose tissue, liver, and placenta and becomes bioactive after C‐terminal proteolytic processing into isoforms with distinct activities. This review summarizes (i) chemerin biosynthesis, processing, receptors, and signaling (
Noha A. Ahmed, Aida A. Hussein, Rehab G. Khalil, Nour Y. S. Yassin, Mohamed A. Abdelaziz, Ayman I. Geddawy, Osama M. Ahmed, Yoel A. Klug   +7 more
wiley   +1 more source

Integrating Traditional Wisdom With Modern Science: Ginsenosides as Antiheart Failure Agents

Cardiovascular Therapeutics, Volume 2026, Issue 1, 2026.
Heart failure (HF), as the terminal stage of various cardiovascular diseases, remains a global health challenge with persistently high morbidity and mortality rates. Although current therapies—including angiotensin receptor–neprilysin inhibitors, sodium‐glucose cotransporter‐2 inhibitors, and cardiac resynchronization therapy—have improved outcomes ...
Li Zhou, Yanhua Li, Wenjie Yin, Xi Gu, Jiana Shi, Fan Yang, Satabdi Datta Choudhury   +6 more
wiley   +1 more source

ACE inhibitors potential in correcting vessel wall anti-aggregation activity among patients with arterial hypertension and metabolic syndrome

Российский кардиологический журнал, 2007
Captopril and fosinopril potential in correcting vascular wall anti-aggregation activity among patients with arterial hypertension (AH) and metabolic syndrome (MS) has been examined.
I. N. Medvedev, I. N. Mezentseva, V. V. Tolmachev   +2 more
doaj  

ACE inhibitor effects of brachial artery structure and function in patients with arterial hypertension

Кардиоваскулярная терапия и профилактика, 2012
Aim. To investigate the effects of an angiotensin-converting enzyme (ACE) inhibitor fosinopril on the structural and functional parameters of brachial arteries (BA) in patients with essential arterial hypertension (EAH). Material and methods.
L. V. Melnikova
doaj   +1 more source

A Comprehensive Review on the Efficacy of Antihypertensives in Patients With End‐Stage Renal Disease

International Journal of Hypertension, Volume 2026, Issue 1, 2026.
End‐stage renal disease (ESRD) patients are particularly susceptible to hypertension, as blood pressure (BP) dysregulation leads to increased mortality and morbidity, especially considering the heightened risk of cardiovascular complications, including myocardial infarction, stroke, and congestive heart failure. Given the lack of specific guidelines on
Oluwakorede Akele, Nnedindu Asogwa, Gennifer Wahbah Makhoul, Khalil El-Gharib, Joanne Ling, Alaukika Agarwal, Vanessa Agberien, Ngowari Pokima, Thomas Gut, Suzanne El-Sayegh, Nidhi Chaudhary   +10 more
wiley   +1 more source

Evaluation of the influence of the therapy with fosinopril and zofenopril on the regulatory-adaptive status of patients with diastolic chronic heart failure

КардиоСоматика, 2019
Aim. Еvaluate the influence of combination therapy with fosinopril or zofenopril on the regulatory-adaptive status (RAS) of patients with diastolic chronic heart failure (CHF). Material and methods. The study includes 80 patients with CHF I-II functional
Svetlana N. Nedvetskaya, Vitalii G. Tregubov, Iosif Z. Shubitidze, Vladimir M. Pokrovskiy   +3 more
doaj   +1 more source

Utilization and Dose Optimization of Angiotensin‐Converting Enzyme Inhibitors in Heart Failure Patients With Reduced Ejection Fraction: A Cross Sectional Study on Implications for Guideline‐Targeted Therapy

Health Science Reports, Volume 8, Issue 11, November 2025.
ABSTRACT Background and Aims Angiotensin‐converting enzyme inhibitors (ACEIs) are well established in reducing morbidity and mortality among patients with chronic heart failure (CHF). Evidence has consistently supported the use of high‐dose ACEI therapy, which is recommended to optimize clinical outcomes and enhance patients' quality of life ...
Martin Kampamba, Ruth Mbanvu, Jimmy Hangoma, Gunet Mwalungali, Mukumbi Mutenda, Audrey Hamachila   +5 more
wiley   +1 more source

Effects of carvedilol, atenolol and their combination with fosinopril on cardiac rhythm variability, clinicofunctional status and quality of life in patients with postinfarction left ventricular dysfunction

Терапевтический архив, 2004
Aim. To study effects ofcarvedilol and atenolol and their combination with fosinopril on heart rhythm variability (HRV), clinicofimctional status and quality of life in postmyocardial infarction patients with moderate chronic cardiac failure (CCF ...
А Т Teplyakov, S V Popov, V V Kalyuzhin, A A Garganeeva, I O Kurlov, V L Nilogov, E V Rybalchenko, S N Shilov   +7 more
doaj  

ANTIHYPERTENSIVE AND VASOPROTECTIVE EFFECTS OF FOSINOPRILE IN PATIENTS WITH ARTERIAL HYPERTENSION

Медицинский совет, 2018
Objective: evaluate antihypertensive and vasoprotective effects of fosinopril in patients with arterial hypertension with a high and very high risk of cardiovascular complications. Material and methods.
N. Yu. Grigorieva, A. N. Kuznetsov, M. E. Koroleva, T. V. Koroleva, O. E. Vilkova   +4 more
doaj   +1 more source